References
- Silverberg E. Cancer statistics. CA 1985; 35: 10–56
- Prostate Cancer, W J Catalona. Grune and Stratton, Orlando 1984
- Reiner W J, Scott W W, Eggleston J C, et al. Long term survival after hormonal therapy for stage D prostate cancer. J Urol 1979; 122: 183–184
- Scher H I, Sternberg C N. Chemotherapy of urologic malignancies. Sem Urol 1985; 3: 239–280
- Scott W W, Johnson D E, Schmidt J E, et al. Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5 fluorouracil: results of first national randomized study. J Urol 1975; 114: 909–911
- Elder J S, Gibbons R P. Results of trials of the USA national prostatic cancer project. Therapeutic Principles in Metastatic Prostate Cancer, F Schroeder, B Richards. Alan R. Liss, New York 1985; 221–242, (EORTC Genitourinary group monograph 2, Part A)
- Einhorn L H. An overview of chemotherapeutic trials in advanced cancer of the prostate. Urological Cancer, D G Skinner. Grune and Stratton, New York 1983; 89–100
- Schmidt J D. Cytotoxic agents effective in prostate cancer. Semin Urol 1983; 1: 299–310
- Torti F M, Carter S K. The chemotherapy of prostatic adenocarcinoma. Ann Intern Med 1980; 92: 681–689
- Einsenberger M A, Simon R, O'Dwyer P J, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827–841
- Kasimis B S, Miller J B, Kaneshiro C A, et al. Cyclophosphamide versus 5FU, doxorubicine and mitomycin C in the treatment of hormone resistant metastatic carcinoma of the prostate: A preliminary report of randomized trial. J Clin Oncol 1985; 3: 385–392
- Torti F M, Aston D, Lum B L, et al. Weekly doxorabicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1983; 1: 477–482
- Gibbons R P. Prostate cancer chemotherapy. Cancer 1987; 60: 586–588